TIB Molbiol develops test kits for Omicron variant detection

pharmafile | December 6, 2021 | News story | Sales and Marketing  

TIB Molbiol, a newly acquired subsidiary of Roche, has developed three new VirSNiP test kits for the detection of mutations in the recently-discovered Omicron variant of COVID-19. The three new Research Use Only (RUO) test kits are intended to help differentiate unique mutations of Omicron from other COVID-19 variants.

VirSNiP variant kits are designed for use on LightCycler and cobas z 480 analysers. The kits include VirSNIP SARS-CoV-2 Spike S373P, VirSNip SARS Spike ins214EPE and VirSNip SARS Spike E484A, and utilise quantitative polymerase chain reaction (qPCR) technology to aid researchers in the improvement of variant detection and viral research.

 “The  COVID-19 pandemic continues to be an evolving and complex situation,” shared Roche Diagnostics CEO, Thomas Schinecker. “The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour.”

The new kits will help analyse the spread of emerging COVID-19 variants, and evaluate the potential impact of vaccines, public health interventions, restrictions, and therapies upon the spread of coronavirus and its mutations.

“There is still much to learn about Omicron,” elaborated Thomas Schinecker. “It’s critical to identify Omicron quickly and accurately, which will help inform ongoing research – including the further development of therapeutics and vaccines – and potentially stop or slow down the advance of this new variant.”

Roche’s VirSNiP variant kits are among the first developed to detect the new Omicron variant mutations, part of a global effort to address the WHO designated ‘Variant of Concern’.

Ana Ovey

Related Content

No items found

Latest content